Open-label, Phase IIIb study to evaluate the efficacy and safety of subcutaneous RoACTEMRA monotherapy in patients with severe Rheumatoid Arthritis being treated with a TNF and experiencing a DAS28 ESR 3.2, using a treat to target approach aiming for improved clinical outcomes

Trial Profile

Open-label, Phase IIIb study to evaluate the efficacy and safety of subcutaneous RoACTEMRA monotherapy in patients with severe Rheumatoid Arthritis being treated with a TNF and experiencing a DAS28 ESR 3.2, using a treat to target approach aiming for improved clinical outcomes

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 May 2016 Status changed from active, no longer recruiting to completed.
    • 23 Jul 2015 Planned number of patients changed from 120 to 160 as reported by United Kingdom Clinical Research Network.
    • 09 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top